By Troy Farah Sep 14, 2019, published in DoubleBlind
"A Canadian company will announce on Monday (September 16) the development of a synthetic drug based on the chemical structure of ibogaine, a psychedelic with a long history of ceremonial use. Mind Medicine Inc. (“Mindmed”) is betting that 18-MC (18-methoxycoronaridine) will be a powerful tool to fight addiction and opioid use disorder.
The National Institute on Drug Abuse (NIDA) previously funded Savant’s 18-MC drug development program to the tune of $6.7 million in 2012, however, the program included only one clinical trial. Mindmed is not only conducting Phase II FDA-approved trials using 18-MC to target opioid use disorder, but also plans to explore LSD, psilocybin, and ketamine to treat mental health."